Drug Profile
Research programme: cholinergic receptor modulators - AlphaSyx Therapeutics
Alternative Names: AT 5355Latest Information Update: 22 Sep 2023
Price :
$50
*
At a glance
- Originator AlphaSyx Therapeutics
- Class Anti-inflammatories; Small molecules
- Mechanism of Action Cholinergic receptor modulators
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Discontinued Neurogenic inflammation
Most Recent Events
- 22 Sep 2023 Discontinued - Preclinical for Neurogenic inflammation in USA (unspecified route)
- 28 Dec 2020 No recent reports of development identified for preclinical development in Neurogenic-inflammation in USA
- 02 Nov 2016 Preclinical trials in Neurogenic inflammation in USA (unspecified route)